Crinetics Pharmaceuticals (CRNX) News Today $35.07 -0.87 (-2.42%) Closing price 03/25/2025 04:00 PM EasternExtended Trading$35.20 +0.13 (+0.37%) As of 03/25/2025 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Crinetics Pharmaceuticals (NASDAQ:CRNX) Now Covered by Analysts at Stifel NicolausMarch 26 at 2:52 AM | americanbankingnews.comStifel Initiates Coverage of Crinetics Pharmaceuticals (CRNX) with Buy RecommendationMarch 25 at 5:37 PM | msn.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) CEO Sells $592,959.60 in StockMarch 24 at 5:39 AM | americanbankingnews.com8,206 Shares in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Purchased by Cibc World Markets CorpCibc World Markets Corp acquired a new position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 8,206 shares of the company's stock, valued aMarch 24 at 3:57 AM | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Sells 13,735 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Connor Clark & Lunn Investment Management Ltd. cut its stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 66.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,898 shares of the company's sMarch 24 at 3:34 AM | marketbeat.comSwiss National Bank Purchases 28,500 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Swiss National Bank lifted its position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 21.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 159,400 shares of the company's stock after acquiring an additionalMarch 23 at 3:45 AM | marketbeat.comProficio Capital Partners LLC Purchases Shares of 14,674 Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Proficio Capital Partners LLC purchased a new stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) during the 4th quarter, according to the company in its most recent filing with the SEC. The fund purchased 14,674 shares of the company's stock, valued at approximately $750March 23 at 3:10 AM | marketbeat.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Insider Dana Pizzuti Sells 2,515 SharesCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) insider Dana Pizzuti sold 2,515 shares of the company's stock in a transaction that occurred on Wednesday, March 19th. The shares were sold at an average price of $34.20, for a total value of $86,013.00. Following the sale, the insider now directly owns 72,233 shares in the company, valued at approximately $2,470,368.60. This represents a 3.36 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.March 22, 2025 | marketbeat.comJeff E. Knight Sells 7,162 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) StockCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) COO Jeff E. Knight sold 7,162 shares of the stock in a transaction dated Wednesday, March 19th. The stock was sold at an average price of $34.20, for a total transaction of $244,940.40. Following the sale, the chief operating officer now owns 87,491 shares in the company, valued at $2,992,192.20. The trade was a 7.57 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.March 22, 2025 | marketbeat.comRichard Scott Struthers Sells 17,338 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) StockCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) CEO Richard Scott Struthers sold 17,338 shares of the business's stock in a transaction that occurred on Wednesday, March 19th. The stock was sold at an average price of $34.20, for a total value of $592,959.60. Following the transaction, the chief executive officer now directly owns 329,147 shares in the company, valued at $11,256,827.40. The trade was a 5.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.March 22, 2025 | marketbeat.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Insider Dana Pizzuti Sells 2,515 SharesMarch 22, 2025 | insidertrades.comIntech Investment Management LLC Has $2.20 Million Stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Intech Investment Management LLC lifted its position in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 92.9% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 43,105 shares of the company's stocMarch 22, 2025 | marketbeat.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Recommendation of "Moderate Buy" from BrokeragesCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) has earned an average recommendation of "Moderate Buy" from the thirteen analysts that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation and twelve have issued a buyMarch 19, 2025 | marketbeat.com18,117 Shares in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Purchased by Skandinaviska Enskilda Banken AB publSkandinaviska Enskilda Banken AB publ bought a new stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 18,117 shares of the company's stock, valued at approximatelyMarch 18, 2025 | marketbeat.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Bought by Charles Schwab Investment Management Inc.Charles Schwab Investment Management Inc. raised its position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 15.8% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 759,126 shares of the company's stock after buyinMarch 16, 2025 | marketbeat.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Sold by Victory Capital Management Inc.Victory Capital Management Inc. decreased its stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 18.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 281,451 shares of the comMarch 13, 2025 | marketbeat.comBank of New York Mellon Corp Has $17.63 Million Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Bank of New York Mellon Corp lifted its stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 10.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 344,765 shares ofMarch 12, 2025 | marketbeat.comCrinetics Pharmaceuticals Announces March 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 10, 2025 | markets.businessinsider.comCrinetics Pharmaceuticals Announces March 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 10, 2025 | globenewswire.comProficio Capital Partners LLC Acquires Shares of 14,674 Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Proficio Capital Partners LLC acquired a new stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 14,674 shares of the company's stock, valued atMarch 9, 2025 | marketbeat.comLisanti Capital Growth LLC Sells 25,875 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Lisanti Capital Growth LLC cut its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 23.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 82,700 shares of the company's stock after selling 25,87March 8, 2025 | marketbeat.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q4 2024 Earnings Call TranscriptMarch 3, 2025 | insidermonkey.comFisher Asset Management LLC Boosts Stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Fisher Asset Management LLC lifted its stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 16.0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 559,287 shares of the company's stock aftMarch 3, 2025 | marketbeat.comCrinetics Pharmaceuticals, Inc (CRNX) Q4 2024 Earnings Call TranscriptMarch 2, 2025 | seekingalpha.comPiper Sandler Remains a Buy on Crinetics Pharmaceuticals (CRNX)March 1, 2025 | markets.businessinsider.comCrinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth PlansMarch 1, 2025 | finance.yahoo.comCrinetics Pharmaceuticals (NASDAQ:CRNX) Trading Up 6.1% After Better-Than-Expected EarningsCrinetics Pharmaceuticals (NASDAQ:CRNX) Shares Up 6.1% Following Earnings BeatMarch 1, 2025 | marketbeat.comCrinetics Pharmaceuticals (NASDAQ:CRNX) Announces Earnings ResultsCrinetics Pharmaceuticals (NASDAQ:CRNX - Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.88) earnings per share for the quarter, beating the consensus estimate of ($0.92) by $0.04.February 28, 2025 | marketbeat.comTD Cowen Sticks to Its Buy Rating for Crinetics Pharmaceuticals (CRNX)February 28, 2025 | markets.businessinsider.comCrinetics reports Q4 EPS (88c), consensus (89c)February 27, 2025 | markets.businessinsider.comIs Crinetics Pharmaceuticals (CRNX) the Worst Performing Mid Cap Stock to Buy According to Analysts?February 27, 2025 | msn.comCrinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateFebruary 27, 2025 | globenewswire.comNew York State Common Retirement Fund Grows Stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)New York State Common Retirement Fund lifted its stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 5.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 155,426 shares of the compFebruary 27, 2025 | marketbeat.comRhumbline Advisers Increases Stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Rhumbline Advisers raised its stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 14.1% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 124,078 shares of the company's stock after purchasing an aFebruary 27, 2025 | marketbeat.comFirst Week of April 17th Options Trading For Crinetics Pharmaceuticals (CRNX)February 26, 2025 | nasdaq.comCrinetics Pharmaceuticals (NASDAQ:CRNX) Sets New 52-Week Low - Should You Sell?Crinetics Pharmaceuticals (NASDAQ:CRNX) Sets New 1-Year Low - Here's What HappenedFebruary 25, 2025 | marketbeat.comCrinetics appoints Tobin Schilke as CFOFebruary 25, 2025 | markets.businessinsider.comCrinetics Pharmaceuticals Appoints Tobin Schilke as Chief Financial OfficerFebruary 24, 2025 | globenewswire.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Rating of "Moderate Buy" from AnalystsCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) has earned an average rating of "Moderate Buy" from the thirteen ratings firms that are covering the company, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and twelve have given a buy recommenFebruary 22, 2025 | marketbeat.comCrinetics Pharmaceuticals to Participate in Two Upcoming March Investor ConferencesFebruary 20, 2025 | globenewswire.comCrinetics Pharmaceuticals (CRNX) Projected to Post Earnings on WednesdayCrinetics Pharmaceuticals (NASDAQ:CRNX) will be releasing earnings after the market closes on Wednesday, February 26. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=663753)February 19, 2025 | marketbeat.comRep. Gilbert Ray Cisneros, Jr. Purchases Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Representative Gilbert Ray Cisneros, Jr. (D-California) recently bought shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX). In a filing disclosed on February 11th, the Representative disclosed that they had bought between $1,001 and $15,000 in Crinetics Pharmaceuticals stock on January 29th. TFebruary 13, 2025 | marketbeat.comCRNX stock touches 52-week low at $35.47 amid market shiftsFebruary 11, 2025 | msn.comCrinetics Pharmaceuticals (NASDAQ:CRNX) Reaches New 1-Year Low - Time to Sell?Crinetics Pharmaceuticals (NASDAQ:CRNX) Sets New 52-Week Low - What's Next?February 11, 2025 | marketbeat.comCrinetics Pharmaceuticals, Inc.: Crinetics Pharmaceuticals Announces February 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 11, 2025 | finanznachrichten.deCrinetics initiated with a Buy at TD CowenFebruary 11, 2025 | markets.businessinsider.comTD Cowen initiates Crinetics stock with Buy rating, sees high potentialFebruary 11, 2025 | msn.comCrinetics Pharmaceuticals (NASDAQ:CRNX) Now Covered by TD CowenTD Cowen began coverage on shares of Crinetics Pharmaceuticals in a research note on Tuesday. They issued a "buy" rating on the stock.February 11, 2025 | marketbeat.comabrdn plc Grows Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)abrdn plc grew its stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 22.3% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 43,389 shares of the company's stock after purchasing an additional 7February 11, 2025 | marketbeat.comCrinetics Pharmaceuticals Announces February 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 10, 2025 | globenewswire.com Remove Ads Get Crinetics Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRNX and its competitors with MarketBeat's FREE daily newsletter. Email Address CRNX Media Mentions By Week CRNX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CRNX News Sentiment▼0.840.79▲Average Medical News Sentiment CRNX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CRNX Articles This Week▼176▲CRNX Articles Average Week Remove Ads Get Crinetics Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRNX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Moderna News Today Genmab A/S News Today Dr. Reddy's Laboratories News Today Viatris News Today Ascendis Pharma A/S News Today Vaxcyte News Today Qiagen News Today Roivant Sciences News Today Sarepta Therapeutics News Today Revolution Medicines News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CRNX) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredNvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredThis Crypto Is Set to Explode in FebruaryBryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Crinetics Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Crinetics Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
